CJC with DAC 5mg
- Estimated Delivery : Up to 4 business days
- Free Shipping: On all orders over £150
Research Use Only
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
What is the CJC-1295
CJC-1295 provides extended GHRH activity. Researchers often investigate this combination to better understand growth hormone dynamics in controlled models.
CJC-1295 Overview
CJC-1295, a GHRH analog, is associated with sustained increases in growth hormone and IGF-1, supporting repair and recovery. CJC-1295 supports for improved body composition, recovery, and anti-aging benefits in clinical research.
History
CJC-1295, a synthetic analog of growth hormone–releasing hormone (GHRH), was developed in the early 2000s to extend the half-life and activity of natural GHRH fragments for research into growth hormone and IGF-1 pathways.
CJC-1295 Structure
CAS #: 446036-97-1
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.9 g/mol
PubChem ID: 91976842
Research Findings
CJC-1295 has been examined in endocrine, metabolic, regenerative, and systemic models, with research exploring their influence on growth hormone pathways, body composition, tissue recovery, and cellular viability. Studies highlight their role in IGF-1 activity, repair processes, and systemic resilience in preclinical settings.
Key Areas of Research:
• Endocrine: Growth hormone, IGF-1, signaling
• Metabolic: Lipids, lean tissue, glucose balance
• Cellular: Proliferation, repair, recovery
• Systemic: Cardiovascular, viability, healing
Together, these findings suggest broad experimental potential for CJC-1295 and Ipamorelin across multiple biological pathways. By modulating growth hormone signaling, influencing metabolic activity, and supporting cellular and systemic recovery, this combination provides a versatile platform for research into regeneration, resilience, and physiological balance in laboratory models.
Teichman S.L. et al., Journal of Clinical Endocrinology & Metabolism, 2006









